Examples of using Vimpat in English and their translations into French
{-}
-
Colloquial
-
Official
Vimpat: start of Phase 3 in epilepsy PGTCS.
Vimpat epilepsy POS2 pediatric adj. therapy Phase 3 results.
Vimpat epilepsy PGCTS6 adj. therapy Phase 3 results 2019.
Vimpat(lacosamide) is available to people living with epilepsy.
Vimpat: positive Phase 3 results in epilepsy POS monotherapy EU.
Vimpat, a drug to treat epilepsy, also progressed nicely in 2014.
The“core products” are UCB's newly launched medicines Cimzia, Vimpat and Neupro.
In September 2014, FDA approved Vimpat(lacosamide) as monotherapy in partial onset seizures.
We accelerate uptake of Briviact while maximizing the potential of Cimzia, Vimpat, Keppra and Neupro;
These comprise our products Cimzia, Vimpat, Neupro, Keppra
Cimzia, Vimpat and Neupro increased their net sales by 23%, reaching almost 250 million EUR.
The U.S. authorities also approved a new single loading dose administration option for all formulations of Vimpat.
Vimpat is scheduled to move into Phase 3 development for primary generalized tonic-clonic seizures(PGTCS)
The Phase 3 study for Vimpat as monotherapy in the treatment of adults with partial-onset seizures generated positive results in October 2015.
We mitigate the loss of exclusivity for Cimzia, Vimpat, and Neupro by continuing growth from Briviact
In the U.S., our largest market, Cimzia, Vimpat and Neupro, increased net sales by 25% to€ 733 million.
we filed for regulatory approval of Vimpat in two major countries: Japan and China.
net sales reached€ 143 million and€ 26 million respectively driven by Cimzia, Vimpat, Neupro and Keppra.
Vimpat(lacosamide), available for people living with epilepsy partial-onset seizures achieved net sales of€ 679 million +44%; CER: +26.
In 2014, combined sales of Cimzia, Vimpat and Neupro reached€ 1 468 million, representing 50% of UCB's global net sales.